B-intervention	0	9	Nebivolol
O	10	16	effect
O	17	19	on
B-condition	20	31	doxorubicin
I-condition	31	32	-
I-condition	32	39	induced
I-condition	40	54	cardiotoxicity
O	55	57	in
O	58	64	breast
O	65	71	cancer
O	71	72	.

O	73	76	The
O	77	80	aim
O	81	83	of
O	84	88	this
O	89	94	study
O	95	98	was
O	99	101	to
O	102	108	assess
O	109	116	whether
O	117	126	nebivolol
O	127	136	treatment
O	137	142	could
O	143	147	have
O	148	158	beneficial
O	159	166	effects
O	167	169	in
O	170	173	the
O	174	184	prevention
O	185	187	of
O	188	202	anthracyclines
O	202	203	-
O	203	210	induced
O	211	225	cardiotoxicity
O	225	226	.

O	227	230	Our
O	231	242	prospective
O	243	248	study
O	249	257	included
B-total-participants	258	260	60
O	261	266	women
O	266	267	,
O	268	272	mean
O	273	276	age
B-age	277	279	52
I-age	279	280	.
I-age	280	281	6
I-age	281	282	±
I-age	282	284	13
I-age	285	290	years
O	290	291	,
B-eligibility	292	296	with
I-eligibility	297	301	HER2
I-eligibility	302	310	negative
I-eligibility	311	317	breast
I-eligibility	318	324	cancer
I-eligibility	324	325	,
I-eligibility	326	335	scheduled
I-eligibility	336	338	to
I-eligibility	339	346	undergo
I-eligibility	347	356	treatment
I-eligibility	357	361	with
I-eligibility	362	373	doxorubicin
O	373	374	.

O	375	378	The
O	379	387	patients
O	388	392	were
O	393	401	randomly
O	402	409	divided
O	410	414	into
O	415	418	two
O	419	425	groups
O	425	426	:
O	427	430	the
O	431	440	treatment
O	441	446	group
O	447	448	(
O	448	449	n
O	449	450	=
B-intervention-participants	450	452	30
O	452	453	)
O	454	459	which
O	460	468	received
O	469	478	nebivolol
O	479	480	5
O	481	483	mg
O	484	488	once
O	489	494	daily
O	495	498	for
O	499	502	the
O	503	511	duration
O	512	514	of
O	515	527	chemotherapy
O	528	531	and
O	532	535	the
B-control	536	543	control
I-control	544	549	group
O	550	551	(
O	551	552	n
O	552	553	=
B-control-participants	553	555	30
O	555	556	)
O	557	564	without
O	565	574	treatment
O	575	579	with
O	580	589	nebivolol
O	589	590	.

O	591	601	Cytostatic
O	602	611	treatment
O	612	615	was
O	616	625	performed
O	626	630	with
O	631	642	doxorubicin
O	643	645	70
O	646	648	mg
O	648	649	/
O	649	651	m2
O	652	664	administered
O	665	678	intravenously
O	679	684	every
O	685	687	21
O	688	692	days
O	693	696	for
O	697	700	six
O	701	707	cycles
O	707	708	.

O	709	712	The
O	713	720	average
O	721	731	cumulative
O	732	736	dose
O	737	739	of
O	740	751	doxorubicin
O	752	755	was
O	756	759	520
O	759	760	±
O	760	761	8
O	762	764	mg
O	764	765	/
O	765	767	m2
O	767	768	.

O	769	785	Echocardiography
O	786	789	was
O	790	799	performed
O	800	811	immediately
O	812	818	before
O	819	822	and
O	823	828	after
O	829	832	six
O	833	839	cycles
O	840	842	of
O	843	854	doxorubicin
O	855	862	therapy
O	862	863	.

O	864	866	We
O	867	872	found
O	873	875	no
O	876	887	significant
O	888	899	differences
O	900	907	between
O	908	911	the
O	912	915	two
O	916	922	groups
O	923	932	regarding
B-outcome	933	941	baseline
I-outcome	942	950	clinical
I-outcome	951	954	and
I-outcome	955	972	echocardiographic
I-outcome	973	983	parameters
O	983	984	.

O	985	988	The
O	989	992	two
O	993	999	groups
O	1000	1007	reached
O	1008	1009	a
O	1010	1017	similar
O	1018	1028	cumulative
O	1029	1033	dose
O	1034	1036	of
O	1037	1048	doxorubicin
O	1048	1049	.

O	1050	1052	No
O	1053	1060	patient
B-outcome	1061	1065	died
O	1066	1072	during
O	1073	1076	the
O	1077	1082	study
O	1082	1083	.

O	1084	1088	None
O	1089	1091	of
O	1092	1095	the
O	1096	1104	patients
B-outcome	1105	1113	withdrew
O	1114	1118	from
O	1119	1131	chemotherapy
O	1131	1132	.

O	1133	1138	After
O	1139	1142	six
O	1143	1149	cycles
O	1150	1152	of
O	1153	1164	doxorubicin
O	1165	1172	therapy
O	1172	1173	,
O	1174	1177	the
B-outcome	1178	1182	left
I-outcome	1183	1194	ventricular
I-outcome	1195	1196	(
I-outcome	1196	1198	LV
I-outcome	1198	1199	)
I-outcome	1200	1208	ejection
I-outcome	1209	1217	fraction
O	1217	1218	,
B-outcome	1219	1229	shortening
I-outcome	1230	1238	fraction
O	1238	1239	,
O	1240	1243	and
B-outcome	1244	1246	LV
I-outcome	1247	1256	diameters
O	1257	1264	changed
O	1264	1265	,
O	1266	1269	but
O	1270	1273	not
O	1274	1287	significantly
O	1287	1288	.

B-outcome	1289	1295	Tissue
I-outcome	1296	1303	Doppler
I-outcome	1304	1311	imaging
I-outcome	1312	1313	(
I-outcome	1313	1316	TDI
I-outcome	1316	1317	)
I-outcome	1318	1326	detected
O	1327	1329	in
O	1330	1333	the
O	1334	1341	control
O	1342	1347	group
O	1348	1349	a
O	1350	1361	significant
O	1362	1370	decrease
O	1371	1373	of
O	1374	1384	myocardial
O	1385	1395	velocities
O	1395	1396	,
O	1397	1407	indicating
O	1408	1409	a
O	1410	1412	LV
O	1413	1422	diastolic
O	1423	1434	dysfunction
O	1434	1435	.

O	1436	1438	In
O	1439	1442	the
O	1443	1447	same
O	1448	1453	group
O	1453	1454	,
O	1455	1462	speckle
O	1463	1471	tracking
O	1472	1479	imaging
O	1480	1481	(
O	1481	1484	STI
O	1484	1485	)
O	1486	1494	revealed
O	1495	1496	a
O	1497	1510	statistically
O	1511	1522	significant
B-outcome	1523	1533	alteration
I-outcome	1534	1536	of
I-outcome	1537	1540	the
I-outcome	1541	1552	ventricular
I-outcome	1553	1564	deformation
O	1564	1565	,
O	1566	1571	which
O	1572	1577	means
O	1578	1579	a
O	1580	1588	decrease
O	1589	1591	in
O	1592	1594	LV
O	1595	1603	systolic
O	1604	1612	function
O	1612	1613	.

O	1614	1616	In
O	1617	1620	the
O	1621	1630	nebivolol
O	1631	1640	treatment
O	1641	1646	group
O	1646	1647	,
O	1648	1650	no
O	1651	1662	significant
B-outcome	1663	1674	alterations
I-outcome	1675	1677	in
I-outcome	1678	1681	the
I-outcome	1682	1684	LV
I-outcome	1685	1693	systolic
I-outcome	1694	1697	and
I-outcome	1698	1707	diastolic
I-outcome	1708	1716	function
O	1717	1721	were
O	1722	1730	observed
O	1730	1731	.

O	1732	1735	The
O	1736	1743	results
O	1744	1746	of
O	1747	1751	this
O	1752	1757	study
O	1758	1762	show
O	1763	1766	the
O	1767	1774	benefit
O	1775	1777	of
O	1778	1781	new
O	1782	1799	echocardiographic
O	1800	1807	imaging
O	1808	1815	methods
O	1816	1820	such
O	1821	1823	as
O	1824	1827	TDI
O	1828	1831	and
O	1832	1835	STI
O	1836	1838	in
O	1839	1842	the
O	1843	1852	screening
O	1853	1855	of
O	1856	1861	early
O	1862	1869	cardiac
O	1870	1881	dysfunction
O	1882	1889	induced
O	1890	1892	by
O	1893	1903	cytostatic
O	1904	1913	treatment
O	1913	1914	.

O	1915	1924	Nebivolol
O	1925	1934	treatment
O	1935	1944	prevented
O	1945	1948	the
O	1949	1959	occurrence
O	1960	1962	of
O	1963	1977	anthracyclines
O	1977	1978	-
O	1978	1985	induced
O	1986	2000	cardiomyopathy
O	2001	2003	in
O	2004	2007	the
O	2008	2013	short
O	2014	2018	term
O	2018	2019	.

O	2020	2022	In
O	2023	2028	order
O	2029	2031	to
O	2032	2039	confirm
O	2040	2045	these
O	2046	2057	preliminary
O	2058	2065	results
O	2065	2066	,
O	2067	2073	larger
O	2074	2081	studies
O	2082	2086	with
O	2087	2088	a
O	2089	2095	longer
O	2096	2102	follow
O	2102	2103	-
O	2103	2105	up
O	2106	2112	period
O	2113	2116	are
O	2117	2125	required
O	2125	2126	.
